CanSino Biologics Inc (CanSinoBIO), a Chinese biopharmaceutical company that is developing a COVID-19 vaccine candidate, plans to raise a total of 5.2 billion yuan ($743 million) in an initial public offering (IPO) on Shanghai’s Nasdaq-style STAR Market, according to a company filing on Thursday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
